The OPUSWAVE Imaging System is built around Terumo’s DualView Imaging Catheter, which combines optical frequency-domain imaging (OFDI) and intravascular ultrasound (IVUS) on a single platform.
The company has announced plans to expand its antibody-drug conjugate (ADC) manufacturing capabilities in Switzerland while also broadening its long-term partnership with a leading, though undisclosed, U.S.-based biopharmaceutical company.
The collaboration aims to turn scientific discoveries into practical healthcare solutions by combining MIT’s research expertise with Abu Dhabi’s expanding life sciences ecosystem.
The initiative brings together SK bioscience, global health nonprofit PATH, consulting firm Slalom and technology partner SK AX to create an evidence-based system that helps researchers evaluate vaccine candidates before they enter costly late-stage clinical trials.
The combined business will operate as Cortigent Holdings and trade on Nasdaq under the ticker symbol CRGT once the transaction closes, expected in the third quarter of 2026, subject to shareholder and regulatory approvals.
The project aims to strengthen medical education while helping Sri Lanka train more healthcare professionals to meet growing national demand.
The rollout follows the device’s receipt of both CE mark and UK Conformity Assessed (UKCA) certification, allowing hospitals and healthcare providers in eligible European countries to begin purchasing the system.
The agreement was announced during the BIO International Convention 2026 in San Diego, California, and is expected to strengthen corneal transplantation services while improving access to sight-restoring care across the UAE and the wider region.
Under the collaboration, Insilico Medicine will use its proprietary Pharma.AI platform to identify and optimise drug candidates that meet predefined scientific and early development criteria.
The test detects the virus by identifying its genetic material in blood samples, allowing health workers to confirm infections quickly and accurately.